Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Capstone Therapeutics Corp. (CAPS : OTC)

• Company Description    Capstone Therapeutics Corp., formerly known as OrthoLogic Corp., is a biotechnology company focused on developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is engaged in the development and commercialization of two product platforms: AZX100 and Chrysalin. AZX100 is a novel synthetic 24-amino acid peptide, a class of compounds in the field of smooth muscle relaxation and fibrosis. AZX100 is currently being evaluated for commercially significant medical applications such as the treatment of pulmonary fibrosis, the prevention of hypertrophic and keloid scarring and intimal hyperplasia. Chrysalin, the Company's novel synthetic 23-amino acid peptide, stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It is currently being evaluated in disorders that involve vascular endothelial dysfunction. Capstone Therapeutics Corp. is headquartered in Tempe, Arizona. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $36.00 Daily Weekly Monthly 20 Day Moving Average: 3 shares Shares Outstanding: 0.08 (millions) Market Capitalization: $2.85 (millions) Beta: 159.71 52 Week High: $37.50 52 Week Low: $6.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% 12.64% 12 Week 2.86% 13.09% Year To Date 108.70% 154.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1275 W. Washington Street Suite 104 - Tempe,AZ 85281 USA ph: 602-286-5520 fax: 602-286-5300 investorinquiries@capstonethx.com http://www.capstonethx.com

• General Corporate Information    Officers John M. Holliman, III - Executive Chairman and Principal Executive Officer Les M. Taeger - Senior Vice President and Chief Financial Officer Elwood D. Howse, Jr. - Director Fredric J. Feldman - Director Michael M. Toporek - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 14068E208 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 0.08 Most Recent Split Date: 9.00 (0.00:1) Beta: 159.71 Market Capitalization: $2.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - - Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - - 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©